Spatial multi-omics work identified shifting macrophage populations across progression of MASLD and proposed markers that could support patient stratification in clinical trials. The study used spatial profiling to connect immune-cell distribution with disease stage in a way that bulk measurements often miss. By focusing on macrophage heterogeneity, researchers reported marker patterns tied to MASLD progression trajectories, aiming to make trial enrollment and biomarker development more precise. For fibrosis- and inflammation-driven indications, macrophage location and composition are increasingly viewed as mechanistic readouts. The immediate biotech relevance is translational: trial designs can use such markers to separate subgroups more likely to respond to anti-inflammatory or anti-fibrotic therapies. It also offers hypothesis-generating targets for combination strategies. No specific therapies were named in the brief, but the approach underscores a practical pathway from omics discovery to biomarker-backed clinical programs.